bpc-157 supplement benefits dosage side effects BPC 157 Dosage: A Doctor's Evidence-Based Guide Sermorelin vs BPC 157: Benefits,

Over 52 weeks, resolution of MASH without worsening of fibrosis was achieved in 10% of the placebo group, 44% of the tirzepatide 5 mg group, 56% of the 10 mg group, and 62% of the 15 mg group

However, the cagrilintide-semaglutide group experienced more adverse events, primarily gastrointestinal disorders affecting 72.5 % of patients compared to 34.4 % in the placebo group

In the Study of Tirzepatide in Participants with Heart Failure with Preserved Ejection Fraction with Obesity (SUMMIT) trial, tirzepatide significantly reduced the risk of death from cardiovascular causes or worsening heart failure events in patients with heart failure with preserved ejection fraction (ejection fraction 50% and above) and obesity (BMI 30 kg/m 2 ), compared with placebo (HR 0.62

Sana A, Arooj N, Mahnoor K